XT
KPTI icon

XTX Topco’s Karyopharm Therapeutics KPTI Stock Holding History

XTX Topco’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Sell
53,272
-111,171
-68% -$964K 0.01% 2416
2026
Q1 		$916K Buy
164,443
+152,539
+1,281% +$1.16M 0.02% 1487
2025
Q4 		$87.6K Sell
11,904
-2,498
-17% -$15.3K ﹤0.01% 2670
2025
Q3 		$94.2K Buy
14,402
+1,346
+10% +$7.24K ﹤0.01% 2034
2025
Q2 		$56.3K Buy
+13,056
New +$64.1K ﹤0.01% 1997
2024
Q4 		– Sell
-1,727
Closed -$21.5K – 2622
2024
Q3 		$21.5K Sell
1,727
-7,645
-82% -$95K ﹤0.01% 1832
2024
Q2 		$122K Sell
9,372
-6,817
-42% -$113K 0.01% 1372
2024
Q1 		$367K Buy
16,189
+12,914
+394% +$226K 0.05% 679
2023
Q4 		$42.5K Sell
3,275
-17,396
-84% -$234K 0.01% 1256
2023
Q3 		$415K Sell
20,671
-4,919
-19% -$110K 0.07% 510
2023
Q2 		$687K Buy
+25,590
New +$1.1M 0.12% 218
2023
Q1 		– Sell
-8,721
Closed -$445K – 1476
2022
Q4 		$445K Buy
8,721
+6,018
+223% +$417K 0.09% 356
2022
Q3 		$221K Sell
2,703
-737
-21% -$55K 0.05% 722
2022
Q2 		$233K Buy
3,440
+2,478
+258% +$227K 0.1% 400
2022
Q1 		$106K Buy
962
+92
+11% +$11.5K 0.05% 504
2021
Q4 		$84K Sell
870
-215
-20% -$21.4K 0.05% 495
2021
Q3 		$95K Buy
+1,085
New +$113K 0.03% 568

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

XTX Topco's KPTI Position: Q2 2026 in Review

XTX Topco reduced its Karyopharm Therapeutics (KPTI) stake by 68% in Q2 2026, selling an estimated $964K and leaving 53,272 shares worth $520K. The position accounts for 0.01% of the portfolio, ranked #2416.

XTX Topco first reported a position in KPTI in Q3 2021 and has held it in 17 quarters since. The position peaked at $916K in Q1 2026. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • XTX Topco held 53,272 shares of Karyopharm Therapeutics worth $520K as of Q2 2026.
  • XTX Topco sold 111,171 Karyopharm Therapeutics shares in Q2 2026, an estimated $964K.
  • Karyopharm Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2416 holding.
  • XTX Topco first reported a position in Karyopharm Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • XTX Topco's Karyopharm Therapeutics position peaked at $916K in Q1 2026.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.